Создание наноструктурных систем для транспорта лекарственных препаратов на основе смеси тритерпеноидов бересты, страница 29

2007. V. 96. P. 595-602.129. Jevprasesphant R, Penny J., Attwood D., McKeown N.B., D'Emanuele A. Engineering ofdendrimer surface to enhance transepithe-lial transport and reduce cytotoxicity //Pharmaceutical Research. 2003 .V. 20. P. 1543-1550.130. D'Emanuele ., Jevprasesphant A., Penny R., Attwood J.

D. The use of a dendrimer-propranololprodrug to bypass efflux transporters and enhance oral bioavailability // Journal of ControlledRelease. 2004. V. 95. P. 447-453.131. Najlah M., Freeman S., Attwood D., D'Emanuele A. In vitro evaluation of dendrimer prodrugfor oral drug // International Journal of Pharmaceutics. 2007. V. 336. P. 183-190.132. Goldberg D.S., Vijayalakshmi N., Swaan PW., Ghandehari H. G35 PAMAM dendrimersenhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity // Journalof Controlled Release.

2011. V. 150. P. 318-325.133. Sweet D.M., Kolhatkar R.B., Ray A., Swaan P., Ghandehari H. Transepithelial transport ofPEGylated anionic poly(amidoamine) dendrimers: Implications for oral drug delivery // Journalof Controlled Release . 2009. V. 138. P. 78-85.134.

Vandamme T.F., Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for oculardelivery of pilocarpine nitrate // Journal ofControlled Release. 2005. V. 20. P. 23-38.135. Agrawal A., Asthana A., Gupta U., Jain NK . Tumor and dendrimers: a review on drug delivery// Journal of Pharmacy and Pharmacology. 2008. V. 60. P.

671-688.152136. Kukowska-Latallo J.F., Candido K.A., Cao Z., NigavekarSS., Majoros I.J., Thomas T.P.,Balogh L.P., Khan M.K., Baker Jr J.R. Nanoparticle targeting of anti-cancer drug improvestherapeutic response in animal model of human epithelial cancer // Cancer Research. 2005. V.65. P. 5318-5324.137. Dass C.R. Vehicles for oligonucleotide delivery to tumors // Journal of Pharmacy andPharmacology. 2002. V. 54.

P. 3-27.138. Tekade R.K., Kumar P.V., Jain N.K . Dendrimers in oncology: an expanding // ChemicalReviews. 2009 . V. 109. P. 49-87.139. Wichterle O., Lim D. Hydrophilic gels for biological use // Nature 185. 1960. P. 117-118.140. Kamath K., Park K . Biodegradable hydrogels in drug delivery // Adv. Drug Deliv. Rev.

1993.V. 11. P. 59-84.141. Schipper N.G.M., Varum K.M., Stenberg P., Ockind G., Lennernais H., Artursson P. Chitosanas absorption enhancers for poorly absorbable drugs 3: influence of mucus on absorptionenhancement // Eur. J. Pharm. Sci.

1999. V. 8. P. 335-343.142. Watzke H.J., Dieschbourg C. Novel silica-biopolymer nanocomposites: the silica sol-gelprocess in biopolymer organogels // Adv. Colloids Interface Sci. 1994 .V. 50. P. 1-14.143. Ohya Y., Shiratani M., Kobayashi H., Ouchi T. Release behavior of 5-fluorouracil fromchitosan-gel nanospheres immobilizing 5-fluorouracil coated with polysaccharides and theircell specific cytotoxicity // Pure Appl. Chem. 1994. V.

31. P. 629-642.144. Shirashi S., Imai T., Otagiri M. Controlled release of indomethacin by chitosan-polyelectrolytecomplex: optimization and in vivo: in vitro evaluation // J. Control. Release. 1993. V. 25. P.217-225.145. Fernandez-Urrusuno.R, Cavlo P., Remunan-Lopez C., Vila-Jato J.L., Alonso M.J.Enhancement of nasal absorption of insulin using chitosan nanoparticles // Pharm.

Res. 1999.V. 16. P. 1576-1581.146. Pan Y., Li Y., Zhao H., Zheng J., Xu H., Wei G., Hao J., Cui F. Chitosan nanoparticles improvethe intestinal absorption of insulin in vivo // Int. J. Pharm. 2002. V. 249. P. 139-147.147. Xu Y., Du Y. Effect of molecular structure of chitosan on protein delivery properties ofchitosan nanoparticles // Int. J. Pharm. 2003. V. 250. P.

215-226.148. Berthold A., Cremer K., Kreuter J. Preparation and characterization of chitosan microspheres asdrug carrier for prednisolone sodium phosphate as model for antiinflammatory drugs // J.Control. Release. 1996. V. 39. P. 17-25.153149. Ray K., Mao H.Q., Lin K.Y., Huang S.K., Leong K.W.

Oral immunization with DNA- chitosannanoparticles // Proc. Int. Symp. Control. Release Mater. 1999. V. 26. P. 348-349.150. Tokumitsu H., Ichikawa H., Fukumori Y. Chitosan-gadopentetic acid complex nanoparticlesfor gadolinium neutron capture therapy of cancer: preparation by novel emulsion-dropletcoalescence technique and characterization // Pharm. Res. 1999. V. 16. P. 1830-1835.151.

Lee K.Y., Kwon I.C., Kim Y.-H., Jo W.H., Jeong S.Y. Structural investigation of chitosanself-aggregates prepared for gene delivery // Proc. Int. Symp. Control. Rel.Bioact. Mater. 1998.V. 25. P. 340-341.152. Uchegbu I.F., Schatzlein A.G., Tetley L., Gray A.I., Sludden J., Siddique S., Mosha E.Polymeric chitosan-based vesicles for drug delivery // J.

Pharm. Pharmacol. 1998. V. 50. P.453-458.153. Lee K.Y., Kwon I.C., Kim Y.-H., Jo W.H., Jeong S.Y. Preparation of chitosan self-aggregatesas a gene delivery system // J. Control. Release. 1998. V. 51. P. 213-220.154. Rajaonarivony M., Vauthier C., Couarraze G., Puisieux F., Couvreur P. Development of a newdrug carrier made from alginate // J. Pharm. Sci. 1993. V. 82 (9). P.

912-917.155. Reis C.P., Ribeiro A.J., Houng S., Veiga F., Neufeld R.J. Nanoparticulate delivery system forinsulin: design, characterization and in vitro/in vivo bioactivity // Eur. J. Pharm. Sci. 2007. V.30 . P. 392-397.156. Pandey R., Khuller G.K.

Nanotechnology based drug delivery system(s) for the managementof tuberculosis // Indian J. Exp. Biol. 2006. V. 44 . P. 357-366.157. Jung T., Breitenbach A., Kissel T. Sulfobutylated poly(vinyl alcohol)-grafted-poly (lactidecoglycolide) facilitate the preparation of small negatively charged biodegradable nanospheresfor protein delivery // J. Control. Release . 2000. V. 67. P. 157-169.158. Rodriguez S.A., Puel F., Briancon S., Allemann E., Doelker E., Fessi H. Comparative scale-upof three methods for producing ibuprofen-loaded nanoparticles // Eur. J.

Pharm. Sci. 2005 . V.25. P. 357-367.159. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymericnanoparticles as drug delivery devices // J. Control. Release. 2001. V. 70. P. 1-20.160. Vinogradov S., Batrakova E., Kabanov A.

Poly(ethyleneglycol)-polyethylenimine nanogelparticles: novel drug delivery systems for antisense oligonucleotides // Colloids Surf. 1999. V.16. P. 291-304.154161. Watts P.J., Davies M.C., Melia C.D. Microencapsulation using emulsification/ solventevaporation: an overview of techniques and applications // Crit Rev. Ther. Drug Carr. Syst.1990. V. 7. P. 235-259.162. Bharali D.J., Sahoo S.K., Mozumdar S., Maitra A.Cross-linked polyvinylpyrrolidonenanoparticles: a potential carrier for hydrophilic drugs // J.

Colloid Interface Sci. 2003. V. 258.P. 415-423.163. Guowei D., Adriane K., Chen X., Jie C., Yinfeng L.PVP magnetic nanospheres:biocompatibility, in vitro and in vivo bleomycin release // Int. J. Pharm. 2006. V. 328. P. 78-85.164. Sahoo S.K., De T.K., Ghosh P.K ., Maitra A. pH- and thermosensitive hydrogel nanoparticles //J. Colloid Interface Sci. 1998. V. 206. P. 361-368.165.

Gupta M., Gupta A.K.. Hydrogel pullulan nanoparticles encapsulating pBUDLacZ plasmid asan efficient gene delivery carrier // J. Control. Release. 2004. V. 99. P. 157-166.166. Kim I.S., Jeong Y.I., Kim S.H. Self-assembled hydrogel nanoparticles composed ofdextran andpoly(ethylene glycol) macromer // Int.

J. Pharm. 2000. V. 205. P. 109-116.167. Neuberger T., Schopf B., Hoffmann H., Hoffmann M., von Rechenberg B. Superpara-magneticnanoparticles for biomedical applications: possibilities and limitations of a new drug deliverysystem // J Magn Magn Mater. 2005. V. 293. P. 483-496.168. Figuerola A., Di Corato R., Manna L., Pellegrino T. From iron oxide nanoparticles towardsadvanced iron-based in organic materials designed for biomedical applications // PharmacolRes . 2010.

V. 62 . P. 126-143.169. Chen J.P., Yang P.C., Ma Y.H, Wu T. Characterization of chitosan magnetic nanoparticles forin situ delivery of tissue plasminogen activator // Carbohydr Polym. 2011. V. 84. P. 364-372.170. Shubayev V.I, Pisanic T.R, Jin S. Magnetic nanoparticles for theragnostics // Adv Drug DelivRev. 2009. V. 61. P. 467-477.171.

Mahmoudi M., Simchi A., Milani A.S., Stroeve P. Cell toxicity of superparamagnetic ironoxide nanoparticles // J Colloid Interface Sci. 2009. V. 336. P. 510-518.172. Dobrovolskaia M.A, McNeil S.E. Immunological properties of engineered nanomaterials //Nat Nano. 2007. V. 2. P. 469-478.173.

Hostetler M.J., Wingate J.E., Zhong C.J. Alkanethiolate gold cluster molecules with corediameters from 1.5 to 5.2 nm: core and monolayer properties as a function of core size //Langmuir. 1998. V. 4. P. 17-30.155174. Gibson J.D., Khanal B.P., Zubarev E.R. Paclitaxel-functionalized gold nanoparticles // J. Am.Chem. Soc. 2007. V. 129. P.

11653-11661.175. Cheng Y., Samia A.C., Meyers J.D., Panagopoulos I., Fei B., Burda C. Highly efficient drugdelivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer // J. Am.Chem. Soc. 2008. V. 130. P. 10643-10647.176. Luo X., Matranga C., Tan S., Alba N., Cui X.T. Carbon nanotube nanoreservior for controlledrelease of antiinflammatory dexamethasone // Biomaterials. 2011. V. 32. P. 6316-6323.177.

Radomski A., Jurasz P., Alonso-Escolano D., Drews M., Morandi M., Malinski T., RadomskiM.W . Nanoparticle-induced platelet aggregation and vascular thrombosis // Br J Pharmacol .2005. V. 146. P. 882-893.178. Kim T.Y., Kim D.W., Chung J.Y. Phase I and pharmacokinetic study of Genexol-PM, acremophor-free, polymeric micelle-formulated paclitaxel, in patients with advancedmalignancies // Clin. Cancer Res. 2004.